vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and INTERFACE INC (TILE). Click either name above to swap in a different company.
INTERFACE INC is the larger business by last-quarter revenue ($349.4M vs $247.1M, roughly 1.4× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 7.0%, a 4.1% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 4.3%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $28.6M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 9.8%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Interface, Inc., headquartered in Atlanta, Georgia, is a global manufacturer of commercial flooring. The company sells modular carpet tiles, luxury vinyl tile, and Nora brand rubber flooring.
ANIP vs TILE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $349.4M |
| Net Profit | $27.5M | $24.4M |
| Gross Margin | — | 38.6% |
| Operating Margin | 14.1% | 10.1% |
| Net Margin | 11.1% | 7.0% |
| Revenue YoY | 29.6% | 4.3% |
| Net Profit YoY | 367.5% | 12.1% |
| EPS (diluted) | $1.14 | $0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $349.4M | ||
| Q3 25 | $227.8M | $364.5M | ||
| Q2 25 | $211.4M | $375.5M | ||
| Q1 25 | $197.1M | $297.4M | ||
| Q4 24 | $190.6M | $335.0M | ||
| Q3 24 | $148.3M | $344.3M | ||
| Q2 24 | $138.0M | $346.6M | ||
| Q1 24 | $137.4M | $289.7M |
| Q4 25 | $27.5M | $24.4M | ||
| Q3 25 | $26.6M | $46.1M | ||
| Q2 25 | $8.5M | $32.6M | ||
| Q1 25 | $15.7M | $13.0M | ||
| Q4 24 | $-10.3M | $21.8M | ||
| Q3 24 | $-24.2M | $28.4M | ||
| Q2 24 | $-2.3M | $22.6M | ||
| Q1 24 | $18.2M | $14.2M |
| Q4 25 | — | 38.6% | ||
| Q3 25 | — | 39.4% | ||
| Q2 25 | — | 39.4% | ||
| Q1 25 | — | 37.3% | ||
| Q4 24 | — | 36.5% | ||
| Q3 24 | — | 37.1% | ||
| Q2 24 | — | 35.4% | ||
| Q1 24 | — | 38.1% |
| Q4 25 | 14.1% | 10.1% | ||
| Q3 25 | 15.9% | 14.6% | ||
| Q2 25 | 6.6% | 13.9% | ||
| Q1 25 | 13.3% | 7.8% | ||
| Q4 24 | -2.3% | 8.8% | ||
| Q3 24 | -13.8% | 12.3% | ||
| Q2 24 | 3.7% | 11.0% | ||
| Q1 24 | 14.8% | 8.4% |
| Q4 25 | 11.1% | 7.0% | ||
| Q3 25 | 11.7% | 12.7% | ||
| Q2 25 | 4.0% | 8.7% | ||
| Q1 25 | 8.0% | 4.4% | ||
| Q4 24 | -5.4% | 6.5% | ||
| Q3 24 | -16.3% | 8.3% | ||
| Q2 24 | -1.7% | 6.5% | ||
| Q1 24 | 13.2% | 4.9% |
| Q4 25 | $1.14 | $0.41 | ||
| Q3 25 | $1.13 | $0.78 | ||
| Q2 25 | $0.36 | $0.55 | ||
| Q1 25 | $0.69 | $0.22 | ||
| Q4 24 | $-0.45 | $0.38 | ||
| Q3 24 | $-1.27 | $0.48 | ||
| Q2 24 | $-0.14 | $0.38 | ||
| Q1 24 | $0.82 | $0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $71.3M |
| Total DebtLower is stronger | — | $181.6M |
| Stockholders' EquityBook value | $540.7M | $640.7M |
| Total Assets | $1.4B | $1.2B |
| Debt / EquityLower = less leverage | — | 0.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $71.3M | ||
| Q3 25 | $262.6M | $187.4M | ||
| Q2 25 | $217.8M | $121.7M | ||
| Q1 25 | $149.8M | $97.8M | ||
| Q4 24 | $144.9M | $99.2M | ||
| Q3 24 | $145.0M | $115.6M | ||
| Q2 24 | $240.1M | $94.2M | ||
| Q1 24 | $228.6M | $89.8M |
| Q4 25 | — | $181.6M | ||
| Q3 25 | — | $307.8M | ||
| Q2 25 | — | $304.4M | ||
| Q1 25 | — | $302.9M | ||
| Q4 24 | — | $302.8M | ||
| Q3 24 | — | $337.9M | ||
| Q2 24 | — | $387.6M | ||
| Q1 24 | — | $391.8M |
| Q4 25 | $540.7M | $640.7M | ||
| Q3 25 | $505.8M | $621.0M | ||
| Q2 25 | $436.8M | $575.0M | ||
| Q1 25 | $418.6M | $513.1M | ||
| Q4 24 | $403.7M | $489.1M | ||
| Q3 24 | $405.9M | $501.6M | ||
| Q2 24 | $455.8M | $451.2M | ||
| Q1 24 | $452.0M | $428.5M |
| Q4 25 | $1.4B | $1.2B | ||
| Q3 25 | $1.4B | $1.3B | ||
| Q2 25 | $1.3B | $1.3B | ||
| Q1 25 | $1.3B | $1.2B | ||
| Q4 24 | $1.3B | $1.2B | ||
| Q3 24 | $1.3B | $1.2B | ||
| Q2 24 | $920.8M | $1.2B | ||
| Q1 24 | $914.5M | $1.2B |
| Q4 25 | — | 0.28× | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | — | 0.53× | ||
| Q1 25 | — | 0.59× | ||
| Q4 24 | — | 0.62× | ||
| Q3 24 | — | 0.67× | ||
| Q2 24 | — | 0.86× | ||
| Q1 24 | — | 0.91× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $49.3M |
| Free Cash FlowOCF − Capex | $29.1M | $28.6M |
| FCF MarginFCF / Revenue | 11.8% | 8.2% |
| Capex IntensityCapex / Revenue | 0.5% | 5.9% |
| Cash ConversionOCF / Net Profit | 1.10× | 2.02× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $121.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $49.3M | ||
| Q3 25 | $44.1M | $76.7M | ||
| Q2 25 | $75.8M | $30.1M | ||
| Q1 25 | $35.0M | $11.7M | ||
| Q4 24 | $15.9M | $38.0M | ||
| Q3 24 | $12.5M | $76.2M | ||
| Q2 24 | $17.4M | $21.5M | ||
| Q1 24 | $18.3M | $12.6M |
| Q4 25 | $29.1M | $28.6M | ||
| Q3 25 | $38.0M | $66.1M | ||
| Q2 25 | $71.8M | $22.8M | ||
| Q1 25 | $32.5M | $4.3M | ||
| Q4 24 | $13.5M | $24.4M | ||
| Q3 24 | $7.7M | $69.7M | ||
| Q2 24 | $13.0M | $12.0M | ||
| Q1 24 | $13.7M | $8.6M |
| Q4 25 | 11.8% | 8.2% | ||
| Q3 25 | 16.7% | 18.1% | ||
| Q2 25 | 34.0% | 6.1% | ||
| Q1 25 | 16.5% | 1.4% | ||
| Q4 24 | 7.1% | 7.3% | ||
| Q3 24 | 5.2% | 20.3% | ||
| Q2 24 | 9.4% | 3.5% | ||
| Q1 24 | 10.0% | 3.0% |
| Q4 25 | 0.5% | 5.9% | ||
| Q3 25 | 2.7% | 2.9% | ||
| Q2 25 | 1.9% | 2.0% | ||
| Q1 25 | 1.3% | 2.5% | ||
| Q4 24 | 1.3% | 4.1% | ||
| Q3 24 | 3.2% | 1.9% | ||
| Q2 24 | 3.2% | 2.8% | ||
| Q1 24 | 3.3% | 1.4% |
| Q4 25 | 1.10× | 2.02× | ||
| Q3 25 | 1.66× | 1.66× | ||
| Q2 25 | 8.87× | 0.93× | ||
| Q1 25 | 2.23× | 0.90× | ||
| Q4 24 | — | 1.75× | ||
| Q3 24 | — | 2.68× | ||
| Q2 24 | — | 0.95× | ||
| Q1 24 | 1.00× | 0.89× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
TILE
| AMS | $205.9M | 59% |
| EAAA | $143.5M | 41% |
